EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Further Extensive Evaluation of GHB‐Pentose as a Novel Biomarker for the Extended Detection of GHB Intake/Administration in Forensic Casework

Katja Gimmler iD, Lana Brockbals iD, Sandra N Poetzsch iD, Francesco Bavato iD, Laura K Schnider iD, Dario A Dornbierer iD, Oliver G Bosch, Boris B Quednow iD, Erich Seifritz, Christian Steuer iD, Thomas Kraemer iD, Andrea E Steuer iD

Drug Testing and Analysis · 04.11.2026

DOI: 10.1002/dta.70183 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Testing and Analysis, online erschienen am 04.11.2026. Verfasst von Katja Gimmler und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Forensic Pharmacology & Toxicology, Zurich Institute of Forensic Medicine, University of Zurich, Zurich, Switzerland. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Stiftung für wissenschaftliche Forschung an der Universität Zürich, Swiss National Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Gamma‐hydroxybutyrate (GHB) detection in forensic toxicology is hampered by its rapid elimination and endogenous occurrence. GHB‐pentose has recently emerged as a promising biomarker capable of extending the detection window of GHB exposure but requires further evaluation in authentic forensic samples. We systematically investigated GHB‐pentose using two independent LC–MS/MS methods based on hydrophilic interaction liquid chromatography (HILIC) and reversed‐phase (RP) chromatography. Positive findings were evaluated against measured GHB concentrations, case information, matrix type, and concordance between analytical methods. Among 2414 urine cases, 97.6% were negative for GHB and GHB‐pentose. GHB‐pentose could be detected in all 21 GHB‐positive urine samples from living individuals and in four GHB‐positive postmortem cases, whereas 20 other postmortem urine samples with elevated GHB concentrations (10–26 mg/L) were negative for GHB‐pentose. Based on toxicological expert assessment performed independently prior to this study, it was assumed that the GHB detected in these cases was more likely the result of postmortem formation than of prior GHB intake. Fourteen GHB‐negative urine samples were positive for GHB‐pentose; eight of these contained case information supporting previous GHB exposure, including three suspected drug‐facilitated crimes sampled 13–16 h after the incident. GHB‐pentose appears to be a highly specific biomarker of exogenous GHB exposure, capable of extending the detection window beyond that of GHB itself and potentially serving as a discriminant between exogenous GHB administration and endogenous, particularly postmortem, GHB formation. Routine LC–MS/MS screening is feasible, even in the absence of a reference standard, supporting its immediate implementation in forensic toxicology workflows.

Schlagwörter

Stichwörter der Autor:innen

DFCGHBGHB‐pentoseLC–MS/MSextended detectionforensic

Autor:innen und Institutionen

  • Department of Forensic Pharmacology & Toxicology, Zurich Institute of Forensic Medicine, University of Zurich, Zurich, Switzerland.
  • Department of Adult Psychiatry and Psychotherapy, University Hospital of Psychiatry Zurich, Zurich, Switzerland.
  • Neuroscience Center Zurich, University of Zurich and Swiss Federal Institute of Technology Zurich, Zurich, Switzerland.
  • Institute of Pharmaceutical Sciences, Swiss Federal Institute of Technology Zurich, Zurich, Switzerland.

ORCID-Profile: Katja Gimmler, Lana Brockbals, Sandra N Poetzsch, Francesco Bavato, Laura K Schnider, Dario A Dornbierer, Boris B Quednow, Christian Steuer, Thomas Kraemer, Andrea E Steuer

Förderung

  • Stiftung für wissenschaftliche Forschung an der Universität Zürich
  • Swiss National Foundation

Zitieren

APA

Gimmler, K., Brockbals, L., Poetzsch, S. N., Bavato, F., Schnider, L. K., Dornbierer, D. A., Bosch, O. G., Quednow, B. B., Seifritz, E., Steuer, C., Kraemer, T., & Steuer, A. E. (2026). Further Extensive Evaluation of GHB‐Pentose as a Novel Biomarker for the Extended Detection of GHB Intake/Administration in Forensic Casework. Drug Testing and Analysis. https://doi.org/10.1002/dta.70183

Vancouver

Gimmler K, Brockbals L, Poetzsch SN, Bavato F, Schnider LK, Dornbierer DA, et al. Further Extensive Evaluation of GHB‐Pentose as a Novel Biomarker for the Extended Detection of GHB Intake/Administration in Forensic Casework. Drug Testing and Analysis. 2026. doi:10.1002/dta.70183

BibTeX
@article{Gimmler2026,
  author = {Gimmler, Katja and Brockbals, Lana and Poetzsch, Sandra N and Bavato, Francesco and Schnider, Laura K and Dornbierer, Dario A and Bosch, Oliver G and Quednow, Boris B and Seifritz, Erich and Steuer, Christian and Kraemer, Thomas and Steuer, Andrea E},
  title = {Further Extensive Evaluation of GHB‐Pentose as a Novel Biomarker for the Extended Detection of GHB Intake/Administration in Forensic Casework},
  journal = {Drug Testing and Analysis},
  year = {2026},
  doi = {10.1002/dta.70183}
}
Kostenlos starten →